http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 12 Feb 2026 07:13:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NewcelX+Ltd.++++++++++++++For%3A+Feb+12/25987158.html si-local-file:///var/storage/secattach/20260212/25987158.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NewcelX+Ltd.++++++++++++++For%3A+Feb+12/25987158.html Thu, 12 Feb 2026 07:13:00 -0500 NCEL O.13800188 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NewcelX+Ltd.++++++++++++++For%3A+Feb+12/25987158.html si-local-file:///var/storage/secattach/20260212/25987158.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NewcelX+Ltd.++++++++++++++For%3A+Feb+12/25987158.html Thu, 12 Feb 2026 07:13:00 -0500 NCEL O.13800188 http://www.streetinsider.com/Corporate+News/NewcelX+publishes+peer-reviewed+study+on+Mazindol+ER+therapy/25987003.html <p>NewcelX Ltd. (NASDAQ: NCEL) announced the publication of a peer-reviewed scientific review on its Mazindol immediate-release/sustained-release therapy in Clinical Drug Investigation, a Springer Nature journal.</p><p>The article, titled "Mazindol Immediate-Release/Sustained-Release (IR/SR): A 50-Year Legacy of Multifaceted Mechanisms and Emerging Therapeutic Potential," examines the drug's mechanisms and therapeutic applications for central nervous system disorders including narcolepsy, ADHD, and substance use disorders.</p><p>NewcelX stated it is engaged in discussions with multiple parties regarding potential licensing and acquisition transactions for Mazindol ER. The company operates under a Contingent Value Right framework where CVR holders receive additional payments based on proceeds from the disposition of certain http://www.streetinsider.com/Corporate+News/NewcelX+publishes+peer-reviewed+study+on+Mazindol+ER+therapy/25987003.html Thu, 12 Feb 2026 07:01:04 -0500 NCEL http://www.streetinsider.com/Press+Releases/NewcelX+Reports+Peer-Reviewed+Publication+Supporting+Mazindol+IRSR+and+Advances+CVR+Monetization+Strategy/25986974.html <div class="xn-content"> <p><b>Publication strengthens scientific positioning as Company progresses strategic discussions related to CVR-linked asset</b></p><p><span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Feb. 12, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:NCEL" idsrc="xmltag.org" >NewcelX Ltd.</span> ("NewcelX" or the "Company") (Nasdaq: NCEL), a clinical-stage biopharmaceutical company advancing stem-cell-derived therapies for Type 1 Diabetes and advancing innovative therapies for central nervous system (CNS) today announced the publication of a comprehensive peer-reviewed scientific review entitled, "Mazindol Immediate-Release/Sustained-Release (IR/SR): A 50-Year Legacy of Multifaceted Mechanisms and Emerging Therapeutic Potential," in <i>Clinical Drug Investigation</i>, a <span value="ACORN:1098455645" idsrc="xmltag.org" >Springer Nature</span> journal. The article is available at: <a target="_blank" href="https://doi.org/10.1007/s40261-025-01510-2" target="_blank" rel="nofollow">https://doi.org/10.1007/s40261-025-01510-2</a>.</p> <div http://www.streetinsider.com/Press+Releases/NewcelX+Reports+Peer-Reviewed+Publication+Supporting+Mazindol+IRSR+and+Advances+CVR+Monetization+Strategy/25986974.html Thu, 12 Feb 2026 07:00:00 -0500 A.10984556 NCEL O.13800188 O.16433397 http://www.streetinsider.com/Press+Releases/NewcelX+Reports+Peer-Reviewed+Publication+Supporting+Mazindol+IRSR+and+Advances+CVR+Monetization+Strategy/25986974.html <div class="xn-content"> <p><b>Publication strengthens scientific positioning as Company progresses strategic discussions related to CVR-linked asset</b></p><p><span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Feb. 12, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:NCEL" idsrc="xmltag.org" >NewcelX Ltd.</span> ("NewcelX" or the "Company") (Nasdaq: NCEL), a clinical-stage biopharmaceutical company advancing stem-cell-derived therapies for Type 1 Diabetes and advancing innovative therapies for central nervous system (CNS) today announced the publication of a comprehensive peer-reviewed scientific review entitled, "Mazindol Immediate-Release/Sustained-Release (IR/SR): A 50-Year Legacy of Multifaceted Mechanisms and Emerging Therapeutic Potential," in <i>Clinical Drug Investigation</i>, a <span value="ACORN:1098455645" idsrc="xmltag.org" >Springer Nature</span> journal. The article is available at: <a target="_blank" href="https://doi.org/10.1007/s40261-025-01510-2" target="_blank" rel="nofollow">https://doi.org/10.1007/s40261-025-01510-2</a>.</p> <div http://www.streetinsider.com/Press+Releases/NewcelX+Reports+Peer-Reviewed+Publication+Supporting+Mazindol+IRSR+and+Advances+CVR+Monetization+Strategy/25986974.html Thu, 12 Feb 2026 07:00:00 -0500 A.10984556 NCEL O.13800188 O.16433397 http://www.streetinsider.com/Press+Releases/NewcelX+Reports+Peer-Reviewed+Publication+Supporting+Mazindol+IRSR+and+Advances+CVR+Monetization+Strategy/25986974.html <div class="xn-content"> <p><b>Publication strengthens scientific positioning as Company progresses strategic discussions related to CVR-linked asset</b></p><p><span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Feb. 12, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:NCEL" idsrc="xmltag.org" >NewcelX Ltd.</span> ("NewcelX" or the "Company") (Nasdaq: NCEL), a clinical-stage biopharmaceutical company advancing stem-cell-derived therapies for Type 1 Diabetes and advancing innovative therapies for central nervous system (CNS) today announced the publication of a comprehensive peer-reviewed scientific review entitled, "Mazindol Immediate-Release/Sustained-Release (IR/SR): A 50-Year Legacy of Multifaceted Mechanisms and Emerging Therapeutic Potential," in <i>Clinical Drug Investigation</i>, a <span value="ACORN:1098455645" idsrc="xmltag.org" >Springer Nature</span> journal. The article is available at: <a target="_blank" href="https://doi.org/10.1007/s40261-025-01510-2" target="_blank" rel="nofollow">https://doi.org/10.1007/s40261-025-01510-2</a>.</p> <div http://www.streetinsider.com/Press+Releases/NewcelX+Reports+Peer-Reviewed+Publication+Supporting+Mazindol+IRSR+and+Advances+CVR+Monetization+Strategy/25986974.html Thu, 12 Feb 2026 07:00:00 -0500 A.10984556 NCEL O.13800188 O.16433397 http://www.streetinsider.com/Press+Releases/NewcelX+Reports+Peer-Reviewed+Publication+Supporting+Mazindol+IRSR+and+Advances+CVR+Monetization+Strategy/25986974.html <div class="xn-content"> <p><b>Publication strengthens scientific positioning as Company progresses strategic discussions related to CVR-linked asset</b></p><p><span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Feb. 12, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:NCEL" idsrc="xmltag.org" >NewcelX Ltd.</span> ("NewcelX" or the "Company") (Nasdaq: NCEL), a clinical-stage biopharmaceutical company advancing stem-cell-derived therapies for Type 1 Diabetes and advancing innovative therapies for central nervous system (CNS) today announced the publication of a comprehensive peer-reviewed scientific review entitled, "Mazindol Immediate-Release/Sustained-Release (IR/SR): A 50-Year Legacy of Multifaceted Mechanisms and Emerging Therapeutic Potential," in <i>Clinical Drug Investigation</i>, a <span value="ACORN:1098455645" idsrc="xmltag.org" >Springer Nature</span> journal. The article is available at: <a target="_blank" href="https://doi.org/10.1007/s40261-025-01510-2" target="_blank" rel="nofollow">https://doi.org/10.1007/s40261-025-01510-2</a>.</p> <div http://www.streetinsider.com/Press+Releases/NewcelX+Reports+Peer-Reviewed+Publication+Supporting+Mazindol+IRSR+and+Advances+CVR+Monetization+Strategy/25986974.html Thu, 12 Feb 2026 07:00:00 -0500 A.10984556 NCEL O.13800188 O.16433397 http://www.streetinsider.com/PRNewswire/NewcelX+Reports+Peer-Reviewed+Publication+Supporting+Mazindol+IRSR+and+Advances+CVR+Monetization+Strategy/25986974.html <div class="xn-content"> <p><b>Publication strengthens scientific positioning as Company progresses strategic discussions related to CVR-linked asset</b></p><p><span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Feb. 12, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:NCEL" idsrc="xmltag.org" >NewcelX Ltd.</span> ("NewcelX" or the "Company") (Nasdaq: NCEL), a clinical-stage biopharmaceutical company advancing stem-cell-derived therapies for Type 1 Diabetes and advancing innovative therapies for central nervous system (CNS) today announced the publication of a comprehensive peer-reviewed scientific review entitled, "Mazindol Immediate-Release/Sustained-Release (IR/SR): A 50-Year Legacy of Multifaceted Mechanisms and Emerging Therapeutic Potential," in <i>Clinical Drug Investigation</i>, a <span value="ACORN:1098455645" idsrc="xmltag.org" >Springer Nature</span> journal. The article is available at: <a target="_blank" href="https://doi.org/10.1007/s40261-025-01510-2" target="_blank" rel="nofollow">https://doi.org/10.1007/s40261-025-01510-2</a>.</p> <div http://www.streetinsider.com/PRNewswire/NewcelX+Reports+Peer-Reviewed+Publication+Supporting+Mazindol+IRSR+and+Advances+CVR+Monetization+Strategy/25986974.html Thu, 12 Feb 2026 07:00:00 -0500 A.10984556 NCEL O.13800188 O.16433397 http://www.streetinsider.com/PRNewswire/NewcelX+Reports+Peer-Reviewed+Publication+Supporting+Mazindol+IRSR+and+Advances+CVR+Monetization+Strategy/25986974.html <div class="xn-content"> <p><b>Publication strengthens scientific positioning as Company progresses strategic discussions related to CVR-linked asset</b></p><p><span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Feb. 12, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:NCEL" idsrc="xmltag.org" >NewcelX Ltd.</span> ("NewcelX" or the "Company") (Nasdaq: NCEL), a clinical-stage biopharmaceutical company advancing stem-cell-derived therapies for Type 1 Diabetes and advancing innovative therapies for central nervous system (CNS) today announced the publication of a comprehensive peer-reviewed scientific review entitled, "Mazindol Immediate-Release/Sustained-Release (IR/SR): A 50-Year Legacy of Multifaceted Mechanisms and Emerging Therapeutic Potential," in <i>Clinical Drug Investigation</i>, a <span value="ACORN:1098455645" idsrc="xmltag.org" >Springer Nature</span> journal. The article is available at: <a target="_blank" href="https://doi.org/10.1007/s40261-025-01510-2" target="_blank" rel="nofollow">https://doi.org/10.1007/s40261-025-01510-2</a>.</p> <div http://www.streetinsider.com/PRNewswire/NewcelX+Reports+Peer-Reviewed+Publication+Supporting+Mazindol+IRSR+and+Advances+CVR+Monetization+Strategy/25986974.html Thu, 12 Feb 2026 07:00:00 -0500 A.10984556 NCEL O.13800188 O.16433397 http://www.streetinsider.com/PRNewswire/NewcelX+Reports+Peer-Reviewed+Publication+Supporting+Mazindol+IRSR+and+Advances+CVR+Monetization+Strategy/25986974.html <div class="xn-content"> <p><b>Publication strengthens scientific positioning as Company progresses strategic discussions related to CVR-linked asset</b></p><p><span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Feb. 12, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:NCEL" idsrc="xmltag.org" >NewcelX Ltd.</span> ("NewcelX" or the "Company") (Nasdaq: NCEL), a clinical-stage biopharmaceutical company advancing stem-cell-derived therapies for Type 1 Diabetes and advancing innovative therapies for central nervous system (CNS) today announced the publication of a comprehensive peer-reviewed scientific review entitled, "Mazindol Immediate-Release/Sustained-Release (IR/SR): A 50-Year Legacy of Multifaceted Mechanisms and Emerging Therapeutic Potential," in <i>Clinical Drug Investigation</i>, a <span value="ACORN:1098455645" idsrc="xmltag.org" >Springer Nature</span> journal. The article is available at: <a target="_blank" href="https://doi.org/10.1007/s40261-025-01510-2" target="_blank" rel="nofollow">https://doi.org/10.1007/s40261-025-01510-2</a>.</p> <div http://www.streetinsider.com/PRNewswire/NewcelX+Reports+Peer-Reviewed+Publication+Supporting+Mazindol+IRSR+and+Advances+CVR+Monetization+Strategy/25986974.html Thu, 12 Feb 2026 07:00:00 -0500 A.10984556 NCEL O.13800188 O.16433397 http://www.streetinsider.com/PRNewswire/NewcelX+Reports+Peer-Reviewed+Publication+Supporting+Mazindol+IRSR+and+Advances+CVR+Monetization+Strategy/25986974.html <div class="xn-content"> <p><b>Publication strengthens scientific positioning as Company progresses strategic discussions related to CVR-linked asset</b></p><p><span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Feb. 12, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:NCEL" idsrc="xmltag.org" >NewcelX Ltd.</span> ("NewcelX" or the "Company") (Nasdaq: NCEL), a clinical-stage biopharmaceutical company advancing stem-cell-derived therapies for Type 1 Diabetes and advancing innovative therapies for central nervous system (CNS) today announced the publication of a comprehensive peer-reviewed scientific review entitled, "Mazindol Immediate-Release/Sustained-Release (IR/SR): A 50-Year Legacy of Multifaceted Mechanisms and Emerging Therapeutic Potential," in <i>Clinical Drug Investigation</i>, a <span value="ACORN:1098455645" idsrc="xmltag.org" >Springer Nature</span> journal. The article is available at: <a target="_blank" href="https://doi.org/10.1007/s40261-025-01510-2" target="_blank" rel="nofollow">https://doi.org/10.1007/s40261-025-01510-2</a>.</p> <div http://www.streetinsider.com/PRNewswire/NewcelX+Reports+Peer-Reviewed+Publication+Supporting+Mazindol+IRSR+and+Advances+CVR+Monetization+Strategy/25986974.html Thu, 12 Feb 2026 07:00:00 -0500 A.10984556 NCEL O.13800188 O.16433397 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NewcelX+Ltd.++++++++++++++For%3A+Jan+29/25912047.html si-local-file:///var/storage/secattach/20260129/25912047.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NewcelX+Ltd.++++++++++++++For%3A+Jan+29/25912047.html Thu, 29 Jan 2026 07:14:00 -0500 NCEL O.13800188 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NewcelX+Ltd.++++++++++++++For%3A+Jan+29/25912047.html si-local-file:///var/storage/secattach/20260129/25912047.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NewcelX+Ltd.++++++++++++++For%3A+Jan+29/25912047.html Thu, 29 Jan 2026 07:14:00 -0500 NCEL O.13800188 http://www.streetinsider.com/Press+Releases/NewcelX+Announces+Updated+Corporate+Presentation+Ahead+of+Key+Spring+2026+Investor+and+Partnering+Conferences/25911883.html <div class="xn-content"> <p class="prntac"><b>Reinforces strategic focus on Type 1 Diabetes cell therapy and highlights expansion of <span>Scientific Advisory Board</span> and leadership team</b></p><p><span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Jan. 29, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.newcelx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NCEL" idsrc="xmltag.org" >NewcelX Ltd.</span></a> (NASDAQ: NCEL) ("NewcelX" or the "Company"), a clinical-stage cell therapy company advancing transformative treatments for chronic metabolic and neurodegenerative diseases, today announced the release of an updated corporate presentation in advance of its participation in several major spring 2026 investor and partnering conferences, including BIO-Europe Spring in <location value="LU/pt..lisbon" idsrc="xmltag.org" >Lisbon</location>.</p> <div id="prni_dvprnejpg574bleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg574bleft" style="width: 400px; http://www.streetinsider.com/Press+Releases/NewcelX+Announces+Updated+Corporate+Presentation+Ahead+of+Key+Spring+2026+Investor+and+Partnering+Conferences/25911883.html Thu, 29 Jan 2026 07:00:00 -0500 NCEL O.13800188 http://www.streetinsider.com/Press+Releases/NewcelX+Announces+Updated+Corporate+Presentation+Ahead+of+Key+Spring+2026+Investor+and+Partnering+Conferences/25911883.html <div class="xn-content"> <p class="prntac"><b>Reinforces strategic focus on Type 1 Diabetes cell therapy and highlights expansion of <span>Scientific Advisory Board</span> and leadership team</b></p><p><span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Jan. 29, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.newcelx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NCEL" idsrc="xmltag.org" >NewcelX Ltd.</span></a> (NASDAQ: NCEL) ("NewcelX" or the "Company"), a clinical-stage cell therapy company advancing transformative treatments for chronic metabolic and neurodegenerative diseases, today announced the release of an updated corporate presentation in advance of its participation in several major spring 2026 investor and partnering conferences, including BIO-Europe Spring in <location value="LU/pt..lisbon" idsrc="xmltag.org" >Lisbon</location>.</p> <div id="prni_dvprnejpg574bleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg574bleft" style="width: 400px; http://www.streetinsider.com/Press+Releases/NewcelX+Announces+Updated+Corporate+Presentation+Ahead+of+Key+Spring+2026+Investor+and+Partnering+Conferences/25911883.html Thu, 29 Jan 2026 07:00:00 -0500 NCEL O.13800188 http://www.streetinsider.com/PRNewswire/NewcelX+Announces+Updated+Corporate+Presentation+Ahead+of+Key+Spring+2026+Investor+and+Partnering+Conferences/25911883.html <div class="xn-content"> <p class="prntac"><b>Reinforces strategic focus on Type 1 Diabetes cell therapy and highlights expansion of <span>Scientific Advisory Board</span> and leadership team</b></p><p><span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Jan. 29, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.newcelx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NCEL" idsrc="xmltag.org" >NewcelX Ltd.</span></a> (NASDAQ: NCEL) ("NewcelX" or the "Company"), a clinical-stage cell therapy company advancing transformative treatments for chronic metabolic and neurodegenerative diseases, today announced the release of an updated corporate presentation in advance of its participation in several major spring 2026 investor and partnering conferences, including BIO-Europe Spring in <location value="LU/pt..lisbon" idsrc="xmltag.org" >Lisbon</location>.</p> <div id="prni_dvprnejpg574bleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg574bleft" style="width: 400px; http://www.streetinsider.com/PRNewswire/NewcelX+Announces+Updated+Corporate+Presentation+Ahead+of+Key+Spring+2026+Investor+and+Partnering+Conferences/25911883.html Thu, 29 Jan 2026 07:00:00 -0500 NCEL O.13800188 http://www.streetinsider.com/PRNewswire/NewcelX+Announces+Updated+Corporate+Presentation+Ahead+of+Key+Spring+2026+Investor+and+Partnering+Conferences/25911883.html <div class="xn-content"> <p class="prntac"><b>Reinforces strategic focus on Type 1 Diabetes cell therapy and highlights expansion of <span>Scientific Advisory Board</span> and leadership team</b></p><p><span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Jan. 29, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.newcelx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NCEL" idsrc="xmltag.org" >NewcelX Ltd.</span></a> (NASDAQ: NCEL) ("NewcelX" or the "Company"), a clinical-stage cell therapy company advancing transformative treatments for chronic metabolic and neurodegenerative diseases, today announced the release of an updated corporate presentation in advance of its participation in several major spring 2026 investor and partnering conferences, including BIO-Europe Spring in <location value="LU/pt..lisbon" idsrc="xmltag.org" >Lisbon</location>.</p> <div id="prni_dvprnejpg574bleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg574bleft" style="width: 400px; http://www.streetinsider.com/PRNewswire/NewcelX+Announces+Updated+Corporate+Presentation+Ahead+of+Key+Spring+2026+Investor+and+Partnering+Conferences/25911883.html Thu, 29 Jan 2026 07:00:00 -0500 NCEL O.13800188 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NewcelX+Ltd.++++++++++++++For%3A+Jan+12/25834040.html si-local-file:///var/storage/secattach/20260112/25834040.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NewcelX+Ltd.++++++++++++++For%3A+Jan+12/25834040.html Mon, 12 Jan 2026 07:13:00 -0500 NCEL O.13800188 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NewcelX+Ltd.++++++++++++++For%3A+Jan+12/25834040.html si-local-file:///var/storage/secattach/20260112/25834040.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NewcelX+Ltd.++++++++++++++For%3A+Jan+12/25834040.html Mon, 12 Jan 2026 07:13:00 -0500 NCEL O.13800188 http://www.streetinsider.com/Press+Releases/NewcelX+Announce+Positive+Results+from+International+Collaborative+Study+Exploring+Advanced+Biomaterial+Approaches+for+Stem+Cell-Derived+Islet+Delivery+in+Type+1+Diabetes+Without+Immune+Suppression/25833848.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Jan. 12, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://newcelx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NCEL" idsrc="xmltag.org" >NewcelX Ltd</span></a>. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today reported the results of an international collaborative research study investigating advanced biomaterial strategies to support the delivery and function of stem cell–derived islets for the treatment of Type 1 Diabetes.</p> <div id="prni_dvprnejpg743cleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg743cleft" title="NewcelX-Logo" src="http://mma.prnewswire.com/media/2809532/NewCelX_Logo.jpg" alt="NewcelX-Logo" align="middle" data-name="url$http%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2809532%2FNewCelX_Logo.jpg" /></div><p>The peer reviewed study, published in Diabetology, a journal dedicated to diabetes research, conducted in collaboration with research groups from the <span value="ACORN:0309791916" http://www.streetinsider.com/Press+Releases/NewcelX+Announce+Positive+Results+from+International+Collaborative+Study+Exploring+Advanced+Biomaterial+Approaches+for+Stem+Cell-Derived+Islet+Delivery+in+Type+1+Diabetes+Without+Immune+Suppression/25833848.html Mon, 12 Jan 2026 07:00:00 -0500 A.03097919 A.15454200 A.30678504 A.50215358 NCEL O.07123365 O.13800188 O.16781342 O.16785964 O.71462702 http://www.streetinsider.com/Press+Releases/NewcelX+Announce+Positive+Results+from+International+Collaborative+Study+Exploring+Advanced+Biomaterial+Approaches+for+Stem+Cell-Derived+Islet+Delivery+in+Type+1+Diabetes+Without+Immune+Suppression/25833848.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Jan. 12, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://newcelx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NCEL" idsrc="xmltag.org" >NewcelX Ltd</span></a>. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today reported the results of an international collaborative research study investigating advanced biomaterial strategies to support the delivery and function of stem cell–derived islets for the treatment of Type 1 Diabetes.</p> <div id="prni_dvprnejpg743cleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg743cleft" title="NewcelX-Logo" src="http://mma.prnewswire.com/media/2809532/NewCelX_Logo.jpg" alt="NewcelX-Logo" align="middle" data-name="url$http%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2809532%2FNewCelX_Logo.jpg" /></div><p>The peer reviewed study, published in Diabetology, a journal dedicated to diabetes research, conducted in collaboration with research groups from the <span value="ACORN:0309791916" http://www.streetinsider.com/Press+Releases/NewcelX+Announce+Positive+Results+from+International+Collaborative+Study+Exploring+Advanced+Biomaterial+Approaches+for+Stem+Cell-Derived+Islet+Delivery+in+Type+1+Diabetes+Without+Immune+Suppression/25833848.html Mon, 12 Jan 2026 07:00:00 -0500 A.03097919 A.15454200 A.30678504 A.50215358 NCEL O.07123365 O.13800188 O.16781342 O.16785964 O.71462702 http://www.streetinsider.com/Press+Releases/NewcelX+Announce+Positive+Results+from+International+Collaborative+Study+Exploring+Advanced+Biomaterial+Approaches+for+Stem+Cell-Derived+Islet+Delivery+in+Type+1+Diabetes+Without+Immune+Suppression/25833848.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Jan. 12, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://newcelx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NCEL" idsrc="xmltag.org" >NewcelX Ltd</span></a>. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today reported the results of an international collaborative research study investigating advanced biomaterial strategies to support the delivery and function of stem cell–derived islets for the treatment of Type 1 Diabetes.</p> <div id="prni_dvprnejpg743cleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg743cleft" title="NewcelX-Logo" src="http://mma.prnewswire.com/media/2809532/NewCelX_Logo.jpg" alt="NewcelX-Logo" align="middle" data-name="url$http%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2809532%2FNewCelX_Logo.jpg" /></div><p>The peer reviewed study, published in Diabetology, a journal dedicated to diabetes research, conducted in collaboration with research groups from the <span value="ACORN:0309791916" http://www.streetinsider.com/Press+Releases/NewcelX+Announce+Positive+Results+from+International+Collaborative+Study+Exploring+Advanced+Biomaterial+Approaches+for+Stem+Cell-Derived+Islet+Delivery+in+Type+1+Diabetes+Without+Immune+Suppression/25833848.html Mon, 12 Jan 2026 07:00:00 -0500 A.03097919 A.15454200 A.30678504 A.50215358 NCEL O.07123365 O.13800188 O.16781342 O.16785964 O.71462702 http://www.streetinsider.com/Press+Releases/NewcelX+Announce+Positive+Results+from+International+Collaborative+Study+Exploring+Advanced+Biomaterial+Approaches+for+Stem+Cell-Derived+Islet+Delivery+in+Type+1+Diabetes+Without+Immune+Suppression/25833848.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Jan. 12, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://newcelx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NCEL" idsrc="xmltag.org" >NewcelX Ltd</span></a>. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today reported the results of an international collaborative research study investigating advanced biomaterial strategies to support the delivery and function of stem cell–derived islets for the treatment of Type 1 Diabetes.</p> <div id="prni_dvprnejpg743cleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg743cleft" title="NewcelX-Logo" src="http://mma.prnewswire.com/media/2809532/NewCelX_Logo.jpg" alt="NewcelX-Logo" align="middle" data-name="url$http%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2809532%2FNewCelX_Logo.jpg" /></div><p>The peer reviewed study, published in Diabetology, a journal dedicated to diabetes research, conducted in collaboration with research groups from the <span value="ACORN:0309791916" http://www.streetinsider.com/Press+Releases/NewcelX+Announce+Positive+Results+from+International+Collaborative+Study+Exploring+Advanced+Biomaterial+Approaches+for+Stem+Cell-Derived+Islet+Delivery+in+Type+1+Diabetes+Without+Immune+Suppression/25833848.html Mon, 12 Jan 2026 07:00:00 -0500 A.03097919 A.15454200 A.30678504 A.50215358 NCEL O.07123365 O.13800188 O.16781342 O.16785964 O.71462702 http://www.streetinsider.com/Press+Releases/NewcelX+Announce+Positive+Results+from+International+Collaborative+Study+Exploring+Advanced+Biomaterial+Approaches+for+Stem+Cell-Derived+Islet+Delivery+in+Type+1+Diabetes+Without+Immune+Suppression/25833848.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Jan. 12, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://newcelx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NCEL" idsrc="xmltag.org" >NewcelX Ltd</span></a>. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today reported the results of an international collaborative research study investigating advanced biomaterial strategies to support the delivery and function of stem cell–derived islets for the treatment of Type 1 Diabetes.</p> <div id="prni_dvprnejpg743cleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg743cleft" title="NewcelX-Logo" src="http://mma.prnewswire.com/media/2809532/NewCelX_Logo.jpg" alt="NewcelX-Logo" align="middle" data-name="url$http%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2809532%2FNewCelX_Logo.jpg" /></div><p>The peer reviewed study, published in Diabetology, a journal dedicated to diabetes research, conducted in collaboration with research groups from the <span value="ACORN:0309791916" http://www.streetinsider.com/Press+Releases/NewcelX+Announce+Positive+Results+from+International+Collaborative+Study+Exploring+Advanced+Biomaterial+Approaches+for+Stem+Cell-Derived+Islet+Delivery+in+Type+1+Diabetes+Without+Immune+Suppression/25833848.html Mon, 12 Jan 2026 07:00:00 -0500 A.03097919 A.15454200 A.30678504 A.50215358 NCEL O.07123365 O.13800188 O.16781342 O.16785964 O.71462702 http://www.streetinsider.com/Press+Releases/NewcelX+Announce+Positive+Results+from+International+Collaborative+Study+Exploring+Advanced+Biomaterial+Approaches+for+Stem+Cell-Derived+Islet+Delivery+in+Type+1+Diabetes+Without+Immune+Suppression/25833848.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location></span>, <span class="legendSpanClass"><chron>Jan. 12, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://newcelx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NCEL" idsrc="xmltag.org" >NewcelX Ltd</span></a>. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today reported the results of an international collaborative research study investigating advanced biomaterial strategies to support the delivery and function of stem cell–derived islets for the treatment of Type 1 Diabetes.</p> <div id="prni_dvprnejpg743cleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg743cleft" title="NewcelX-Logo" src="http://mma.prnewswire.com/media/2809532/NewCelX_Logo.jpg" alt="NewcelX-Logo" align="middle" data-name="url$http%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2809532%2FNewCelX_Logo.jpg" /></div><p>The peer reviewed study, published in Diabetology, a journal dedicated to diabetes research, conducted in collaboration with research groups from the <span value="ACORN:0309791916" http://www.streetinsider.com/Press+Releases/NewcelX+Announce+Positive+Results+from+International+Collaborative+Study+Exploring+Advanced+Biomaterial+Approaches+for+Stem+Cell-Derived+Islet+Delivery+in+Type+1+Diabetes+Without+Immune+Suppression/25833848.html Mon, 12 Jan 2026 07:00:00 -0500 A.03097919 A.15454200 A.30678504 A.50215358 NCEL O.07123365 O.13800188 O.16781342 O.16785964 O.71462702